Premium
Hepatocellular toxicity during the treatment of refractory acute leukemia with indicine N‐oxide
Author(s) -
Letendre Louis,
Ludwig Jurgen,
Perrault Jean,
Smithson William A.,
Kovach John S.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19841001)54:7<1256::aid-cncr2820540704>3.0.co;2-s
Subject(s) - medicine , refractory (planetary science) , leukemia , toxicity , acute leukemia , gastroenterology , myeloid leukemia , cancer , complete remission , chemotherapy , astrobiology , physics
Indicine N‐oxide is the first member of the large class of compounds comprised of pyrrolizidine alkaloids and their N‐oxides to be studied in the treatment of cancer in humans. Twenty‐two patients with refractory acute leukemia received indicine N‐oxide daily for 5 consecutive days in a dose‐seeking study. Of eight patients with refractory acute lymphocytic leukemia, one had a complete remission, and one had a partial remission. Of 11 patients with refractory acute nonlymphocytic leukemia, 2 patients had complete remissions. Of three patients with blast crisis of chronic granulocytic leukemia, one patient had a partial remission. Five patients had severe hepatic toxicity, probably due to venoocclusive disease induced by the drug. Whether hepatotoxicity and antileukemic activity are a result of the same mechanism of action of indicine N‐oxide is not known.